ICU鲍氏不动杆菌的感染现状及耐药性分析

Current status of Acinetobacter baumannii infection in ICU and analysis of drug resistances

目的探讨ICU中鲍氏不动杆菌的感染现状及耐药性,为临床合理使用抗菌药物提供必要的病原学依据。方法对ICU 2008年1月-2010年7月医院感染的799株鲍氏不动杆菌及其耐药性进行回顾性分析。结果鲍氏不动杆菌分离率为20.6%,且呈逐年升高趋势;鲍氏不动杆菌对常用抗菌药物的耐药率非常严重,对多黏菌素耐药率最低为0,除头孢哌酮/舒巴坦耐药率为49.7%外,对其他抗菌药物的耐药率均>50.0%,其中对亚胺培南耐药率>90.0%。结论 ICU中鲍氏不动杆菌的感染及耐药问题日益严重,需要加强ICU医院感染的检测和耐药菌监控,预防医院感染暴发流行。

OBJECTIVE To explore the current status of Acinetobacter baumannii infections in ICU and the analyzed the drug resistance so as to provide pathological evidence for the clinical reasonable use of antibiotics. METHODS A total of 799 strains of A. baumannii, which were isolated from ICU between Jan 2008 to Jul 2010, were analyzed retrospectively, the drug resistance was observed as well. RESULTS The isolation rate of the A. bau-rnannii strains was 20. 6%, showing an increasing trend. A. baumannii strains were highly resistant to the commonly used antibiotics, the drug resistance rate to polymyxin was the lowest （0）, the drug resistance rates were all higher than 50. 0% except 49.7 % to cefoperazone/sulbactam, the drug resistance rate to imipenem was higher than 90. 0%. CONCLUSION The A. baurnannii infections in the ICU and the drug resistance are increasingly serious, thus it is necessary to intensify the detection of nosocomial infection in the ICU as well as the monitoring of drug resistant strains so as to prevent the outbreak and prevalence of nosocomial infections.